Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Gloria Westney is active.

Publication


Featured researches published by Gloria Westney.


COPD: Journal of Chronic Obstructive Pulmonary Disease | 2012

A combined pulmonary -radiology workshop for visual evaluation of COPD: study design, chest CT findings and concordance with quantitative evaluation

R. Graham Barr; Eugene Berkowitz; Francesca Bigazzi; Frederick Bode; Jessica Bon; Russell P. Bowler; Caroline Chiles; James D. Crapo; Gerard J. Criner; Jeffrey L. Curtis; Asger Dirksen; Mark T. Dransfield; Goutham Edula; Leif Erikkson; Adam L. Friedlander; Warren B. Gefter; David S. Gierada; P. Grenier; Jonathan G. Goldin; MeiLan K. Han; Nadia N. Hansel; Francine L. Jacobson; Hans-Ulrich Kauczor; Vuokko L. Kinnula; David A. Lipson; David A. Lynch; William MacNee; Barry J. Make; A. James Mamary; Howard Mann

Abstract The purposes of this study were: to describe chest CT findings in normal non-smoking controls and cigarette smokers with and without COPD; to compare the prevalence of CT abnormalities with severity of COPD; and to evaluate concordance between visual and quantitative chest CT (QCT) scoring. Methods: Volumetric inspiratory and expiratory CT scans of 294 subjects, including normal non-smokers, smokers without COPD, and smokers with GOLD Stage I-IV COPD, were scored at a multi-reader workshop using a standardized worksheet. There were 58 observers (33 pulmonologists, 25 radiologists); each scan was scored by 9–11 observers. Interobserver agreement was calculated using kappa statistic. Median score of visual observations was compared with QCT measurements. Results: Interobserver agreement was moderate for the presence or absence of emphysema and for the presence of panlobular emphysema; fair for the presence of centrilobular, paraseptal, and bullous emphysema subtypes and for the presence of bronchial wall thickening; and poor for gas trapping, centrilobular nodularity, mosaic attenuation, and bronchial dilation. Agreement was similar for radiologists and pulmonologists. The prevalence on CT readings of most abnormalities (e.g. emphysema, bronchial wall thickening, mosaic attenuation, expiratory gas trapping) increased significantly with greater COPD severity, while the prevalence of centrilobular nodularity decreased. Concordances between visual scoring and quantitative scoring of emphysema, gas trapping and airway wall thickening were 75%, 87% and 65%, respectively. Conclusions: Despite substantial inter-observer variation, visual assessment of chest CT scans in cigarette smokers provides information regarding lung disease severity; visual scoring may be complementary to quantitative evaluation.


Chest | 2011

Racial Differences in Quality of Life in Patients With COPD

MeiLan K. Han; Douglas Curran-Everett; Mark T. Dransfield; Gerard J. Criner; Lening Zhang; James Murphy; Nadia N. Hansel; Dawn L. DeMeo; Nicola A. Hanania; Elizabeth A. Regan; Barry J. Make; Fernando J. Martinez; Gloria Westney; Marilyn G. Foreman

BACKGROUND Although COPD is associated with significant health-related quality-of-life (HRQL) impairment, factors influencing HRQL in patients with COPD are not well understood, particularly in African Americans. We hypothesized that HRQL in COPD differs by race and sought to identify factors associated with those differences. METHODS We analyzed 224 African American and 1,049 Caucasian subjects with COPD enrolled in the COPDGene (Genetic Epidemiology of COPD) Study whose conditions were classified as GOLD (Global Initiative for Chronic Obstructive Lung Disease) stages I to IV. HRQL and symptoms were compared using the St. George Respiratory Questionnaire (SGRQ) and the modified Medical Research Council Dyspnea (MMRC) scale. We constructed a mixed-effects linear regression model for SGRQ score. RESULTS African Americans were younger and reported fewer pack-years of smoking, more current smoking, and less attained education than Caucasians; MMRC scores were higher (P = .02) as were SGRQ scores (mean score difference, 8.4; P < .001). In a general linear model of SGRQ total score after adjusting for factors such as age, sex, and pack-years of smoking, SGRQ total score was similar for African Americans and Caucasians who reported no COPD exacerbations in the prior year. However, for subjects with exacerbations, SGRQ total score was increased to a greater relative extent for African Americans than for Caucasians (1.89 points for each exacerbation, P = .006). For hospitalized exacerbations, the effect on SGRQ total score also was greater for African Americans (4.19 points, P = .04). Furthermore, a larger percentage of African Americans reported having had at least one exacerbation that required hospitalization in the prior year (32% vs 16%, P < .001). CONCLUSION In analyses that account for other variables that affect quality of life, HRQL is similar for African Americans and Caucasians with COPD without exacerbations but worse for African Americans who experience exacerbations, particularly hospitalized exacerbations.


Critical Care Clinics | 2002

Catastrophic antiphospholipid syndrome in the intensive care unit

Gloria Westney; E. Nigel Harris

CAPS is characterized by development of widespread microvascular thrombosis. Patients at risk are those with positive aCL or LA factor. Precipitating events, such as infection, trauma, surgical procedures, or reduction in anticoagulation therapy, may contribute to the development of CAPS. Presentation to the ICU can be dramatic, with progressive multiorgan failure and need for rapid institution of life-supporting measures. Cardiopulmonary failure has been the major contributor to mortality. A variety of therapeutic modalities have been used in an attempt to offset the widespread thrombosis and organ damage from high aCL levels. Anticoagulation therapy and high dosages of steroids seem to have a positive effect on survival.


Lung | 2007

Comorbid Illnesses and Chest Radiographic Severity in African-American Sarcoidosis Patients

Gloria Westney; Sadia Habib; Alexander Quarshie

Sarcoidosis disease expression differs along racial/ethnic lines and black race has been cited as a poor prognostic factor. Besides genetic, healthcare, and socioeconomic factors, comorbid illnesses may influence sarcoidosis disease expression. We set out to investigate the association between comorbid illnesses and chest radiographic severity in a population of African-American sarcoidosis patients. The study was designed as a retrospective database analysis. The hospital and outpatient databases of the Grady Health System were searched to capture adult patients between November 1999 and December 2003 with the ICD-9 codes of 135 or 519.8, along with all associated secondary and tertiary diagnostic codes. Patient electronic pathology and radiographic reports were reviewed for tissue biopsies showing noncaseating granulomas and for chest radiographic Scadding stage. A total of 165 African-American patients were identified (64% female, 43 ± 10 years old). Ninety percent (149/165) had comorbid illnesses. The most frequent chronic comorbid illnesses were hypertension (39%), diabetes mellitus (19%), anemia (19%), asthma (15%), gastroesophageal reflux disease (15%), depression (13%), and heart failure (10%). Females had increased frequency and clustering of chronic illnesses. Chest radiographic stages were more severe in patients with anemia, depression, and those less than 40 years old. Males, within each chronic illnesses category, had more severe CXR stages compared to females; however, significance was not achieved. We concluded that most adult patients with sarcoidosis have comorbid illnesses and these, in addition to gender differences, may influence sarcoidosis disease expression. Screening for comorbid illnesses should be an important aspect of sarcoidosis patient management.


Preventing Chronic Disease | 2017

Impact of Comorbidities Among Medicaid Enrollees With Chronic Obstructive Pulmonary Disease, United States, 2009

Gloria Westney; Marilyn G. Foreman; Junjun Xu; Marshaleen Henriques King; Eric L. Flenaugh; George Rust

Introduction Multimorbidity, the presence of 2 or more chronic conditions, frequently affects people with chronic obstructive pulmonary disease (COPD). Many have high-cost, highly complex conditions that have a substantial impact on state Medicaid programs. We quantified the cost of Medicaid-insured patients with COPD co-diagnosed with other chronic disorders. Methods We used nationally representative Medicaid claims data to analyze the impact of comorbidities (other chronic conditions) on the disease burden, emergency department (ED) use, hospitalizations, and total health care costs among 291,978 adult COPD patients. We measured the prevalence of common conditions and their influence on COPD-related and non–COPD-related resource use by using the Elixhauser Comorbidity Index. Elixhauser comorbidity counts were clustered from 0 to 7 or more. We performed multivariable logistic regression to determine the odds of ED visits by Elixhauser scores adjusting for age, sex, race/ethnicity, and residence. Results Acute care, hospital bed days, and total Medicaid-reimbursed costs increased as the number of comorbidities increased. ED visits unrelated to COPD were more common than visits for COPD, especially in patients self-identified as black or African American (designated black). Hypertension, diabetes, affective disorders, hyperlipidemia, and asthma were the most prevalent comorbid disorders. Substance abuse, congestive heart failure, and asthma were commonly associated with ED visits for COPD. Female sex was associated with COPD-related and non–COPD-related ED visits. Conclusion Comorbidities markedly increased health services use among people with COPD insured with Medicaid, although ED visits in this study were predominantly unrelated to COPD. Achieving excellence in clinical practice with optimal clinical and economic outcomes requires a whole-person approach to the patient and a multidisciplinary health care team.


Sarcoidosis Vasculitis and Diffuse Lung Diseases | 2014

The WASOG sarcoidosis organ assessment instrument: An update of a previous clinical tool

Marc A. Judson; U. Costabel; M. Drent; A. Wells; L. Maier; L. Koth; H. Shigemitsu; D. A. Culver; Jeffrey M. Gelfand; D. Valeyre; N. Sweiss; Elliot D. Crouser; A. S. Morgenthau; E. E. Lower; Arata Azuma; M. Ishihara; S. Morimoto; T. Yamaguchi; N. Shijubo; J. C. Grutters; M. Rosenbach; Huiping Li; Paola Rottoli; Yoshikazu Inoue; Antje Prasse; R. P. Baughman; Robert P. Baughman; Norman Soskel; Athol U. Wells; Elliott Crouser


Clinics in Chest Medicine | 2006

Racial and Ethnic Disparities in Sarcoidosis: From Genetics to Socioeconomics

Gloria Westney; Marc A. Judson


Sarcoidosis Vasculitis and Diffuse Lung Diseases | 2006

Hospitalization for patients with sarcoidosis: 1979-2000.

Marilyn G. Foreman; David M. Mannino; L. Kamugisha; Gloria Westney


Chest | 2000

Radiographic Criteria in ARDS

Gloria Westney


Chest | 2007

CANCER MANIFESTATIONS IN AN AFRICAN AMERICAN SARCOIDOSIS COHORT

Binu George; Gloria Westney

Collaboration


Dive into the Gloria Westney's collaboration.

Top Co-Authors

Avatar

Marilyn G. Foreman

Morehouse School of Medicine

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

James Murphy

University of Colorado Denver

View shared research outputs
Top Co-Authors

Avatar

Mark T. Dransfield

University of Alabama at Birmingham

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Dawn L. DeMeo

Brigham and Women's Hospital

View shared research outputs
Top Co-Authors

Avatar

Eric L. Flenaugh

Morehouse School of Medicine

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge